IL2 and prostate carcinoma: Interestingly, a human study demonstrated that patients with prostate cancer treated with a standard treatment of zoledronate (medication to reduce calcium loss from bones due to cancer) and IL‐2 for 12 months had significantly increased survival rates compared to those just treated with zoledronate alone [38].